GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » Shiller PE Ratio

Infant Bacterial Therapeutics AB (STU:9IB) Shiller PE Ratio : (As of Apr. 25, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Infant Bacterial Therapeutics AB Shiller PE Ratio Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Shiller PE Ratio Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Infant Bacterial Therapeutics AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Infant Bacterial Therapeutics AB's Shiller PE Ratio

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Shiller PE Ratio falls into.


;
;

Infant Bacterial Therapeutics AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Infant Bacterial Therapeutics AB's E10 for the fiscal year that ended in Dec24 is calculated as:

For example, Infant Bacterial Therapeutics AB's adjusted earnings per share data for the fiscal year that ended in Dec24 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec24 (Change)*Current CPI (Dec24)
=-0.883/132.9872*132.9872
=-0.883

Current CPI (Dec24) = 132.9872.

Infant Bacterial Therapeutics AB Annual Data

Earnings per Share (Diluted) CPI Adj_EPS
201512 -1.087 100.276 -1.442
201612 -0.776 102.022 -1.012
201712 -0.609 103.793 -0.780
201812 -0.366 105.912 -0.460
201912 -0.394 107.766 -0.486
202012 -0.630 108.296 -0.774
202112 -0.390 112.486 -0.461
202212 -0.530 126.365 -0.558
202312 -0.890 131.912 -0.897
202412 -0.883 132.987 -0.883

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Infant Bacterial Therapeutics AB  (STU:9IB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Infant Bacterial Therapeutics AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines